Table 1.
Baseline Demographic and Clinical Characteristics: Survey Respondents versus Nonrespondents
| Medicare beneficiaries (N = 1400) | Commercially insured patients (N = 1400) | |||||
|---|---|---|---|---|---|---|
| Characteristics | Survey respondents (N = 258) | Survey nonrespondents (N = 1142) | P value | Survey respondents (N = 210) | Survey nonrespondents (N = 1190) | P value |
| Age, yrs, mean ± SD (median) | 66.7 ± 7.6 (67.5) | 66.6 ± 8.6 (68.0) | .732 | 51.4 ± 10.7 (53.0) | 50.3 ± 10.1 (52.0) | .154 |
| Female sex, N (%) | 150 (58.1) | 650 (56.9) | .728 | 118 (56.2) | 610 (51.3) | .203 |
| Geographic region, N (%) | ||||||
| Northeast | 12 (4.7) | 18 (1.6) | <.001 | a | a | <.001 |
| Midwest | 69 (26.7) | 218 (19.1) | 50 (23.8) | 142 (11.9) | ||
| South | 157 (60.9) | 784 (68.7) | 154 (73.3) | 1011 (85.0) | ||
| West | 20 (7.8) | 122 (10.7) | a | 34 (2.9) | ||
| RxRisk-V comorbidity score, mean ± SD (median) | 1.1 ± 1.8 (0.0) | 1.1 ± 1.7 (0.0) | .483 | 0.3 ± 0.9 (0.0) | 0.3 ± 1.0 (0.0) | .878 |
| Premailing injection/infusion utilization (2007-Nov 2016), N (%) | 65 (25.2) | 215 (18.8) | .025 | 142 (67.6) | 736 (61.8) | .122 |
| Years diagnosed with PsA,b N, mean (SD) | 12.2 (11.0) | N/Ab | — | 9.9 (8.9) | N/Ab | — |
| Years since first symptoms of PsA,b N, mean (SD) | 18.4 (13.7) | N/Ab | — | 15.3 (10.7) | N/Ab | — |
| PsA severity reported by patients, N (%) | ||||||
| Mild | 66 (25.6) | N/Ab | — | 73 (34.8) | N/Ab | — |
| Moderate | 124 (48.1) | N/Ab | — | 107 (51.0) | N/Ab | — |
| Severe | 66 (25.6) | N/Ab | — | 30 (14.3) | N/Ab | — |
a
Suppressed in accordance with privacy rules from the Health Information Portability and Accountability Act, because cell count was <10.
b
These measures were collected from the survey and therefore were not available for nonrespondents.
N/A indicates not applicable; PsA, psoriatic arthritis; SD, standard deviation.